Uncover the next big thing with 18 elite penny stocks that balance risk and reward.
To own UnitedHealth Group, you generally need to be comfortable with a large insurer leaning heavily on government programs while working to keep Medicare margins within targets. The latest dividend affirmation and Medicare Advantage retrenchment do not eliminate the key near term catalyst, which is management’s effort to reset Medicare profitability, nor the biggest risk, which remains higher than expected care utilization eating into margins.
The decision to exit Medicare Advantage plans covering more than 600,000 members and accept an expected 1.1 million enrollment decline by 2026 is the announcement that most directly frames this news. It ties the dividend and capital returns to a business mix that is shrinking in some Medicare segments while management pursues updated margin goals and pricing, which are central to how shorter term earnings outcomes could evolve.
Yet for all the focus on margins today, investors should also be aware that ...
Read the full narrative on UnitedHealth Group (it's free!)
UnitedHealth Group's narrative projects $498.6 billion revenue and $23.5 billion earnings by 2029. This requires 3.5% yearly revenue growth and a $9.4 billion earnings increase from $14.1 billion.
Uncover how UnitedHealth Group's forecasts yield a $475.23 fair value, a 18% upside to its current price.
Some of the lowest ranked analysts see a harsher path than consensus, even before this news, with revenue growth of only 1.9% a year and earnings of about US$21.8 billion by 2029, so if you worry about government scrutiny permanently compressing margins, their more pessimistic view of UnitedHealth’s government exposure may feel closer to your own.
Explore 21 other fair value estimates on UnitedHealth Group - why the stock might be worth over 2x more than the current price!
Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.
These stocks are moving-our analysis flagged them today. Act fast before the price catches up:
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com